Drug · DIN 02435411
SIMBRINZA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 18, 2018; first marketed February 17, 2015.
- Drug Identification Number (DIN)
- 02435411
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Suspension
- Route
- Ophthalmic
- Therapeutic class (ATC)
- Brinzolamide, combinations S01EC54
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BRINZOLAMIDE | 1 % | W/V |
| BRIMONIDINE TARTRATE | 0.2 % | W/V |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 23, 2017: NOC 19002New Drug Submission (NDS) · Transfer of drug identification number
- December 11, 2014: NOC 16427New Drug Submission (NDS)